Is the price fair?
What EXEL's price assumes
Exelixis, Inc. trades at 18.6× earnings against 32.4× for the median Biotechnology name, cheaper than its own group.
18.6
Trailing P/E · Biotechnology median 32.4 · cheaper than the typical name in its group
- Price / sales
- 4.94
Price / sales · as of 2026-Q1
- Free cash flow yield
- 7.0%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +1.1%
Growth the price implies · The price pays for +1.1% free cash flow growth a year for a decade; the business has delivered +51% a year over the last three.
Details›
- Price / book2026-Q1
- 6.06
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $918M
- Market capitalisation
- $13.0B
- 3-year revenue growth
- +13%
- 3-year free cash flow growth
- +51%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $53.37 |
| Its own P/E history, median | $82.99 |
| Its own P/E history, upper quartile | $129.41 |
| 52-week range | $34.54 – $56.74 |
| Today | $56.07 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.